title: [Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].
abstract: OBJECTIVE
  To study correlations between parameters of lipid metabolism and ECG in patients with schizophrenia in light of therapy with atypical antipsychotics.
  
  
  METHODS
  We examined 42 patients with paranoid schizophrenia. All patients received atypical neuroleptics - seroquel, zyprexa, and rispolept. A group of controls included 25 healthy people.
  
  
  RESULTS
  There was a significant increase (p=0.0002) in body mass (in average by 1.5 kg) in 88% patients. A significant increase in the concentration of serum triglycerides was identified as well. The concentration of VLDL in the patients with schizophrenia was 2 times higher compared to controls. After treatment, VLDL concentration increased even more considerably An increase in atherogenic index (AI) was up to 3.1 in patients with schizophrenia compared to 2.2 in controls. After treatment, Al increased up to 4 that demonstrated the high risk of development of atherosclerosis. A significant increase in QT interval in the ECG and heart rate (p=0.03) was revealed only in patients receiving rispolept. In patients receiving zyprexa and seroquel only heart rate was increased.
  
  
  CONCLUSIONS
  The antipsychotics studied increase the risk of development of cardiovascular pathology.
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: L P
authors.initials: LP
authors.lastname: Smirnova
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: D A
authors.initials: DA
authors.lastname: Parshukova
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: Yu N
authors.initials: YN
authors.lastname: Borodyuk
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: E G
authors.initials: EG
authors.lastname: Kornetova
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: G D
authors.initials: GD
authors.lastname: Tkacheva
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: A A
authors.initials: AA
authors.lastname: Seregin
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: T G
authors.initials: TG
authors.lastname: Burdovitsina
authors.affiliation: Mental Health Research Institute, Tomsk.
authors.forename: A V
authors.initials: AV
authors.lastname: Semke
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D050197:Atherosclerosis / Q000097:blood / Q000139:chemically induced*; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015430:Weight Gain; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D008079:Lipoproteins, VLDL; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine